Predictive Role of Soluble B‐Cell Maturation Antigen in Short‐Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study
Journal of Clinical Laboratory Analysis · 2025-02 · 39 (4)
DOI: 10.1002/jcla.25151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 16.01.2025. Verfasst von Laura Caponi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pathology Laboratory, Pisa University Hospital, Department of Translational Research and New Technologies in Medicine, University of Pisa, P…. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
The management of multiple myeloma is challenging because the disease is incurable and unexpected relapses can threaten a patient's survival. Several assessment systems are currently available, but they often require invasive or costly procedures (e.g., instrumental bone marrow and whole‐body examinations) or rely on non‐specific markers in blood and urine that may not be sufficient to assess and monitor the disease.
Aims
To address some of these limitations, the aim of this study was to evaluate the potential use of soluble B‐Cell Maturation Antigen (BCMA), a promising new serum biomarker, as a toll for moniting multiple myeloma patients. Materials & Methods An unselected cohort of 57 newly diagnosed or relapsed myeloma patients was followed up for 6 months after starting a new therapy. Soluble BCMA levels were measured in peripheral blood using a simple and inexpensive ELISA assay.
Results
Soluble BCMA was detectable in peripheral blood by a simple and inexpensive assay in all patients, even in non‐secretory disease or during BCMA‐targeted therapies, and significant changes in its levels were observed over time. The analysis showed that the decrease in sBCMA at 1 and 6 months reflects the quality of the clinical response to anti‐myeloma regimens. Discussion & Conclusion The data provide interesting insights into the usefulness of sBCMA as a non‐invasive tool for early assessment of treatment efficacy. Its simple and cost‐effective detection in peripheral blood could provide clinicians with an addiotional resource for monitoring disease progression and tailoring treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pathology Laboratory, Pisa University Hospital, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
- Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
ORCID-Profile: Maria Livia Del Giudice
Förderung
- Pfizer
Zitieren
APA
Caponi, L., Del Giudice, M. L., Botti, A., Ursino, S., Gennari, A., Paolicchi, A., Galimberti, S., & Buda, G. (2025). Predictive Role of Soluble B‐Cell Maturation Antigen in Short‐Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study. Journal of Clinical Laboratory Analysis, 39(4). https://doi.org/10.1002/jcla.25151
Vancouver
Caponi L, Del Giudice ML, Botti A, Ursino S, Gennari A, Paolicchi A, et al. Predictive Role of Soluble B‐Cell Maturation Antigen in Short‐Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study. Journal of Clinical Laboratory Analysis. 2025;39(4). doi:10.1002/jcla.25151
BibTeX
@article{Caponi2025,
author = {Caponi, Laura and Del Giudice, Maria Livia and Botti, Alice and Ursino, Silvia and Gennari, Alberto and Paolicchi, Aldo and Galimberti, Sara and Buda, Gabriele},
title = {Predictive Role of Soluble B‐Cell Maturation Antigen in Short‐Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study},
journal = {Journal of Clinical Laboratory Analysis},
year = {2025},
volume = {39},
number = {4},
doi = {10.1002/jcla.25151}
}
EUVIMED